Clinical, immunophenotypic, and genotypic characteristics of adult T-ALL as a function of ERG/BAALC expression level
| . | Total . | BAALC expression . | ERG expression . | ERG/BAALC expression . | P . | |||
|---|---|---|---|---|---|---|---|---|
| High, n (%) . | Low, n (%) . | High, n (%) . | Low, n (%) . | Combined, n (%) . | Low, n (%) . | |||
| Total, no. (%) | 187 | 47 (25) | 140 (75) | 94 (50) | 93 (50) | 106 (57) | 81 (43) | |
| TCR subsets analyzed, no. (%) | 157 | |||||||
| Immature | 51 (33) | 24 (47) | 27 (53) | 27 (53) | 24 (47) | 34 (67) | 17 (33) | NS |
| Pre-αβ | 66 (42) | 10 (15) | 56 (85) | 28 (42) | 38 (58) | 32 (48) | 34 (52) | NS |
| TCR+ | 40 (25) | 8 (20) | 32 (80) | 25 (63) | 15 (37) | 25 (63) | 15 (37) | NS |
| EGIL, no. (%) | 184 | |||||||
| 1 or 2 | 55 (30) | 25 (45) | 30 (55) | 34 (62) | 21 (38) | 41 (75) | 14 (25) | .001* |
| 3 | 104 (57) | 15 (14) | 89 (86) | 41 (39) | 63 (61) | 46 (44) | 58 (56) | NS |
| 4 | 25 (13) | 7 (28) | 18 (72) | 17 (68) | 8 (32) | 17 (68) | 8 (32) | NS |
| Genotype subsets analyzed, no. (%) | 186 | |||||||
| CALM-AF10 | 7 (4) | 3 (43) | 4 (57) | 4 (57) | 3 (43) | 4 (57) | 3 (43) | NS |
| SIL-TAL1 | 16 (9) | 2 (13) | 14 (87) | 9 (56) | 7 (44) | 9 (56) | 7 (44) | NS |
| TLX1 | 40 (21) | 1 (2) | 39 (98) | 13 (32) | 27 (68) | 14 (35) | 26 (65) | .002* |
| TLX3 | 17 (9) | 3 (18) | 14 (82) | 8 (47) | 9 (53) | 8 (47) | 9 (53) | NS |
| None of the above | 106 (57) | 37 (35) | 69 (65) | 62 (58) | 44 (42) | 70 (66) | 36 (34) | .002* |
| N/F mutation | 127 (68) | 34 (27) | 93 (73) | 66 (52) | 61 (48) | 74 (58) | 53 (42) | NS |
| Clinical subsets analyzed | ||||||||
| Sex, male, no. (%) | 151 (81) | 33 (70) | 118 (84) | 77 (82) | 74 (80) | 86 (81) | 65 (80) | NS |
| Median age, y | 30 | 30 | 30 | 30 | 30 | 29 | 30 | NS |
| Age > 35 y, no. (%) | 64 (34) | 16 (34) | 48 (34) | 31 (33) | 33 (35) | 34 (32) | 30 (37) | NS |
| Median, WBC × 109/L | 48 | 43 | 55 | 73 | 37 | 64 | 40 | .04* |
| WBC > 100 × 109/L, no. (%) | 63 (34) | 14 (30) | 49 (35) | 39 (42) | 24 (26) | 41 (39) | 22 (27) | NS |
| Mediastinal involvement, no. (%) | 90 (49) | 20 (43) | 70 (51) | 42 (45) | 48 (53) | 46 (44) | 44 (56) | NS |
| CNS involvement, no. (%) | 15 (8) | 3 (7) | 12 (9) | 5 (5) | 10 (11) | 7 (7) | 8 (10) | NS |
| CR, no. (%) | 172 (92) | 42 (90) | 130 (93) | 85 (90) | 87 (94) | 95 (90) | 77 (95) | NS |
| Relapse, no. (%) | 70 (41) | 13 (31) | 57 (44) | 36 (42) | 34 (39) | 41 (43) | 29 (38) | NS |
| . | Total . | BAALC expression . | ERG expression . | ERG/BAALC expression . | P . | |||
|---|---|---|---|---|---|---|---|---|
| High, n (%) . | Low, n (%) . | High, n (%) . | Low, n (%) . | Combined, n (%) . | Low, n (%) . | |||
| Total, no. (%) | 187 | 47 (25) | 140 (75) | 94 (50) | 93 (50) | 106 (57) | 81 (43) | |
| TCR subsets analyzed, no. (%) | 157 | |||||||
| Immature | 51 (33) | 24 (47) | 27 (53) | 27 (53) | 24 (47) | 34 (67) | 17 (33) | NS |
| Pre-αβ | 66 (42) | 10 (15) | 56 (85) | 28 (42) | 38 (58) | 32 (48) | 34 (52) | NS |
| TCR+ | 40 (25) | 8 (20) | 32 (80) | 25 (63) | 15 (37) | 25 (63) | 15 (37) | NS |
| EGIL, no. (%) | 184 | |||||||
| 1 or 2 | 55 (30) | 25 (45) | 30 (55) | 34 (62) | 21 (38) | 41 (75) | 14 (25) | .001* |
| 3 | 104 (57) | 15 (14) | 89 (86) | 41 (39) | 63 (61) | 46 (44) | 58 (56) | NS |
| 4 | 25 (13) | 7 (28) | 18 (72) | 17 (68) | 8 (32) | 17 (68) | 8 (32) | NS |
| Genotype subsets analyzed, no. (%) | 186 | |||||||
| CALM-AF10 | 7 (4) | 3 (43) | 4 (57) | 4 (57) | 3 (43) | 4 (57) | 3 (43) | NS |
| SIL-TAL1 | 16 (9) | 2 (13) | 14 (87) | 9 (56) | 7 (44) | 9 (56) | 7 (44) | NS |
| TLX1 | 40 (21) | 1 (2) | 39 (98) | 13 (32) | 27 (68) | 14 (35) | 26 (65) | .002* |
| TLX3 | 17 (9) | 3 (18) | 14 (82) | 8 (47) | 9 (53) | 8 (47) | 9 (53) | NS |
| None of the above | 106 (57) | 37 (35) | 69 (65) | 62 (58) | 44 (42) | 70 (66) | 36 (34) | .002* |
| N/F mutation | 127 (68) | 34 (27) | 93 (73) | 66 (52) | 61 (48) | 74 (58) | 53 (42) | NS |
| Clinical subsets analyzed | ||||||||
| Sex, male, no. (%) | 151 (81) | 33 (70) | 118 (84) | 77 (82) | 74 (80) | 86 (81) | 65 (80) | NS |
| Median age, y | 30 | 30 | 30 | 30 | 30 | 29 | 30 | NS |
| Age > 35 y, no. (%) | 64 (34) | 16 (34) | 48 (34) | 31 (33) | 33 (35) | 34 (32) | 30 (37) | NS |
| Median, WBC × 109/L | 48 | 43 | 55 | 73 | 37 | 64 | 40 | .04* |
| WBC > 100 × 109/L, no. (%) | 63 (34) | 14 (30) | 49 (35) | 39 (42) | 24 (26) | 41 (39) | 22 (27) | NS |
| Mediastinal involvement, no. (%) | 90 (49) | 20 (43) | 70 (51) | 42 (45) | 48 (53) | 46 (44) | 44 (56) | NS |
| CNS involvement, no. (%) | 15 (8) | 3 (7) | 12 (9) | 5 (5) | 10 (11) | 7 (7) | 8 (10) | NS |
| CR, no. (%) | 172 (92) | 42 (90) | 130 (93) | 85 (90) | 87 (94) | 95 (90) | 77 (95) | NS |
| Relapse, no. (%) | 70 (41) | 13 (31) | 57 (44) | 36 (42) | 34 (39) | 41 (43) | 29 (38) | NS |
NS indicates not significant.
P < .05.